Spots Global Cancer Trial Database for ovarian serous adenocarcinoma

Every month we try and update this database with for ovarian serous adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer	NCT01116648	Fallopian Tube ... Ovarian Endomet... Ovarian High Gr... Ovarian Serous ... Ovarian Serous ... Primary Periton... Triple-Negative...	Biopsy Biospecimen Col... Cediranib Malea... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Olaparib	18 Years -	National Cancer Institute (NCI)
The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors	NCT03641287	Ovarian Cancer Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Ovarian Adenoca... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Primary Periton... Primary Periton...	Exercise Counse... Aerobic Exercis... Physiological S... Quality-of-Life... Questionnaire A... Best Practice	18 Years -	University of Washington
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT00719303	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Primary Periton... Stage IIA Fallo... Stage IIA Ovari... Stage IIB Fallo... Stage IIB Ovari... Stage IIC Fallo... Stage IIC Ovari... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Undifferentiate... Undifferentiate...	Behavioral Diet... Compliance Moni... Counseling Educational Int... Exercise Interv... Laboratory Biom... Quality-of-Life... Questionnaire A...	18 Years -	GOG Foundation
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer	NCT05415709	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Endomet... Ovarian Mucinou... Ovarian Serous ... Primary Periton... Primary Periton... Stage III Fallo... Stage III Ovari... Stage III Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA1 Fal... Stage IIIA1 Ova... Stage IIIA2 Fal... Stage IIIA2 Ova... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima...	Carboplatin Cisplatin Cytoreductive S... Hyperthermic In... Paclitaxel Quality-of-Life... Questionnaire A...	18 Years -	Ohio State University Comprehensive Cancer Center
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	NCT01074411	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Brenner... Ovarian Clear C... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Serous ... Ovarian Transit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Undifferentiate... Undifferentiate...	Bortezomib Carboplatin Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors	NCT05074472	Solid Tumor, Ad... Pancreatic Duct... Ovarian Serous ... Biliary Cancer ... Ovarian Serous ...	ZB131	18 Years -	ZielBio, Inc.
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer	NCT00989651	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Brenner... Ovarian Carcino... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Primary Periton... Stage IIA Fallo... Stage IIA Ovari... Stage IIB Fallo... Stage IIB Ovari... Stage IIC Fallo... Stage IIC Ovari... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Bevacizumab Carboplatin Cisplatin Laboratory Biom... Paclitaxel Veliparib	18 Years -	National Cancer Institute (NCI)
Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity	NCT02016833	Ovarian Serous ... Undifferentiate... Cervical Cancer Cervical Intrae... Acute Myeloid L... Chronic Myeloid...	Blood Sampling	18 Years - 70 Years	PX Biosolutions
The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors	NCT03641287	Ovarian Cancer Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Ovarian Adenoca... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Primary Periton... Primary Periton...	Exercise Counse... Aerobic Exercis... Physiological S... Quality-of-Life... Questionnaire A... Best Practice	18 Years -	University of Washington
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer	NCT05451849	Mesothelioma Mesotheliomas P... Mesothelioma, M... Mesothelioma Pe... Ovarian Cancer Ovarian Serous ... Pancreatic Canc... Pancreatic Aden... Colorectal Canc... Triple Negative... TNBC - Triple-N... Ovarian Adenoca... Pancreatic Neop... Colorectal Neop... Ovarian Neoplas... Cholangiocarcin... Non Small Cell ...	TC-510 Fludarabine Cyclophosphamid...	18 Years -	TCR2 Therapeutics
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	NCT01074411	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Brenner... Ovarian Clear C... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Serous ... Ovarian Transit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Undifferentiate... Undifferentiate...	Bortezomib Carboplatin Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers	NCT02179970	Pancreatic Aden... Ovarian Serous ... Colorectal Canc...	Plerixafor	16 Years -	Cambridge University Hospitals NHS Foundation Trust
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02923739	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Ovarian Adenoca... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Bevacizumab Emactuzumab Laboratory Biom... Paclitaxel Pharmacological...	18 Years -	M.D. Anderson Cancer Center
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer	NCT00108745	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Brenner... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Clinical Observ... Laboratory Biom... Paclitaxel Paclitaxel Poli... Quality-of-Life...	-	GOG Foundation
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery	NCT04498117	Carcinoma, Ovar... Ovarian Neoplas... Ovarian Cancer Ovarian Serous ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Peritoneal Canc... Peritoneal Carc... Peritoneal Neop...	Oregovomab Paclitaxel Carboplatin Placebo Carboplatin	18 Years -	CanariaBio Inc.
To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers	NCT02179970	Pancreatic Aden... Ovarian Serous ... Colorectal Canc...	Plerixafor	16 Years -	Cambridge University Hospitals NHS Foundation Trust
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer	NCT02068794	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Laboratory Biom... Mesenchymal Ste... Oncolytic Measl...	18 Years -	Mayo Clinic
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	NCT01167712	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Brenner... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Stage IIA Fallo... Stage IIA Ovari... Stage IIB Fallo... Stage IIB Ovari... Stage IIC Fallo... Stage IIC Ovari... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Bevacizumab Carboplatin Computed Tomogr... Paclitaxel Therapeutic Con...	18 Years -	National Cancer Institute (NCI)
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	NCT00888615	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Brenner... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Elesclomol Sodi... Paclitaxel	18 Years -	GOG Foundation
First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	NCT01097746	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... FIGO Stage III ... FIGO Stage IIIA... FIGO Stage IIIA... FIGO Stage IIIA... FIGO Stage IIIA... FIGO Stage IIIA... FIGO Stage IIIB... FIGO Stage IIIC... FIGO Stage IVA ... FIGO Stage IVB ... Malignant Ovari... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Primary Periton...	Bevacizumab Carboplatin Paclitaxel	18 Years -	M.D. Anderson Cancer Center
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)	NCT03648489	Ovarian Cancer Ovarian Neoplas... Ovarian Carcino... Ovarian Serous ... Ovarian Endomet... Ovarian Clear C... Fallopian Tube ... Fallopian Tube ... Primary Periton... Primary Periton...	Paclitaxel TAK228	18 Years -	Imperial College London
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer	NCT01116648	Fallopian Tube ... Ovarian Endomet... Ovarian High Gr... Ovarian Serous ... Ovarian Serous ... Primary Periton... Triple-Negative...	Biopsy Biospecimen Col... Cediranib Malea... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Olaparib	18 Years -	National Cancer Institute (NCI)
Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT01504126	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Undiffe... Primary Periton... Stage II Fallop... Stage II Ovaria... Stage IIA Fallo... Stage IIA Ovari... Stage IIB Fallo... Stage IIB Ovari... Stage IIC Fallo... Stage IIC Ovari... Stage III Fallo... Stage III Ovari... Stage III Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Chemotherapy Propranolol Hyd... Quality-of-Life... Therapeutic Con...	18 Years -	M.D. Anderson Cancer Center
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	NCT00262847	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Ovarian Brenner... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Serous ... Ovarian Transit... Primary Periton... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Undifferentiate... Undifferentiate...	Bevacizumab Carboplatin Laboratory Biom... Paclitaxel Placebo Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors	NCT05074472	Solid Tumor, Ad... Pancreatic Duct... Ovarian Serous ... Biliary Cancer ... Ovarian Serous ...	ZB131	18 Years -	ZielBio, Inc.
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer	NCT05451849	Mesothelioma Mesotheliomas P... Mesothelioma, M... Mesothelioma Pe... Ovarian Cancer Ovarian Serous ... Pancreatic Canc... Pancreatic Aden... Colorectal Canc... Triple Negative... TNBC - Triple-N... Ovarian Adenoca... Pancreatic Neop... Colorectal Neop... Ovarian Neoplas... Cholangiocarcin... Non Small Cell ...	TC-510 Fludarabine Cyclophosphamid...	18 Years -	TCR2 Therapeutics
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT00719303	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Primary Periton... Stage IIA Fallo... Stage IIA Ovari... Stage IIB Fallo... Stage IIB Ovari... Stage IIC Fallo... Stage IIC Ovari... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Undifferentiate... Undifferentiate...	Behavioral Diet... Compliance Moni... Counseling Educational Int... Exercise Interv... Laboratory Biom... Quality-of-Life... Questionnaire A...	18 Years -	GOG Foundation
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer	NCT02502266	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Cediranib Cediranib Malea... Computed Tomogr... Magnetic Resona... Olaparib Paclitaxel Pegylated Lipos... Questionnaire A... Topotecan Topotecan Hydro...	18 Years -	National Cancer Institute (NCI)
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02923739	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Ovarian Adenoca... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Bevacizumab Emactuzumab Laboratory Biom... Paclitaxel Pharmacological...	18 Years -	M.D. Anderson Cancer Center
First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	NCT01097746	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... FIGO Stage III ... FIGO Stage IIIA... FIGO Stage IIIA... FIGO Stage IIIA... FIGO Stage IIIA... FIGO Stage IIIA... FIGO Stage IIIB... FIGO Stage IIIC... FIGO Stage IVA ... FIGO Stage IVB ... Malignant Ovari... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Primary Periton...	Bevacizumab Carboplatin Paclitaxel	18 Years -	M.D. Anderson Cancer Center
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	NCT00565851	Clear Cell Aden... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Mucinous Adenoc... Ovarian Brenner... Ovarian Clear C... Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Undifferentiate...	Bevacizumab Carboplatin Docetaxel Gemcitabine Hyd... Laboratory Biom... Paclitaxel Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion	NCT04919629	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Serous ... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Bevacizumab Biopsy Biospecimen Col... Pegcetacoplan Pembrolizumab Questionnaire A...	18 Years -	Roswell Park Cancer Institute
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer	NCT05605535	Ovarian Neoplas... Ovarian Cancer Fallopian Tube ... Peritoneal Carc... Ovarian Serous ...	Oregovomab Paclitaxel Carboplatin Placebo	18 Years -	CanariaBio Inc.
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial	NCT04575935	Advanced Ovaria... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Serous ... Ovarian Transit... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima...	Chemotherapy Laparotomy Minimally Invas... Quality-of-Life... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)	NCT03648489	Ovarian Cancer Ovarian Neoplas... Ovarian Carcino... Ovarian Serous ... Ovarian Endomet... Ovarian Clear C... Fallopian Tube ... Fallopian Tube ... Primary Periton... Primary Periton...	Paclitaxel TAK228	18 Years -	Imperial College London
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer	NCT02364713	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Platinum-Resist... Platinum-Resist... Platinum-Resist... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Bevacizumab Gemcitabine Hyd... Laboratory Biom... Oncolytic Measl... Paclitaxel Pegylated Lipos... Quality-of-Life... Topotecan Hydro...	18 Years -	Mayo Clinic
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)	NCT05001282	Ovarian Cancer Ovarian Neoplas... Ovarian Carcino... Endometrial Can... Ovary Cancer Ovary Neoplasm Ovary Disease Ovary Metastasi... Ovarian Disease... Ovarian Cancer ... Ovarian Epithel... Ovarian Adenoca... Ovarian Serous ... Ovarian Neoplas... Ovarian Cancer ... Endometrial Dis... Endometrial Ade... Endometrial Car... Endometrial Cle... Endometrioid Ad... Endometrial Neo... Endometrial Can... Endometrioid Tu... Fallopian Tube ... Peritoneal Canc...	ELU001	18 Years -	Elucida Oncology
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors	NCT05074472	Solid Tumor, Ad... Pancreatic Duct... Ovarian Serous ... Biliary Cancer ... Ovarian Serous ...	ZB131	18 Years -	ZielBio, Inc.
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer	NCT05605535	Ovarian Neoplas... Ovarian Cancer Fallopian Tube ... Peritoneal Carc... Ovarian Serous ...	Oregovomab Paclitaxel Carboplatin Placebo	18 Years -	CanariaBio Inc.
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation	NCT02953457	BRCA1 Gene Muta... BRCA2 Gene Muta... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Durvalumab Laboratory Biom... Olaparib Tremelimumab	18 Years -	Roswell Park Cancer Institute
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer	NCT02101788	Borderline Ovar... Micropapillary ... Ovarian Serous ... Primary Periton... Recurrent Ovari... Recurrent Prima...	Letrozole Paclitaxel Pegylated Lipos... Quality-of-Life... Questionnaire A... Tamoxifen Citra... Topotecan Trametinib Dime...	18 Years -	National Cancer Institute (NCI)
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors	NCT05074472	Solid Tumor, Ad... Pancreatic Duct... Ovarian Serous ... Biliary Cancer ... Ovarian Serous ...	ZB131	18 Years -	ZielBio, Inc.
Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity	NCT02016833	Ovarian Serous ... Undifferentiate... Cervical Cancer Cervical Intrae... Acute Myeloid L... Chronic Myeloid...	Blood Sampling	18 Years - 70 Years	PX Biosolutions
Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT01504126	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Undiffe... Primary Periton... Stage II Fallop... Stage II Ovaria... Stage IIA Fallo... Stage IIA Ovari... Stage IIB Fallo... Stage IIB Ovari... Stage IIC Fallo... Stage IIC Ovari... Stage III Fallo... Stage III Ovari... Stage III Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Chemotherapy Propranolol Hyd... Quality-of-Life... Therapeutic Con...	18 Years -	M.D. Anderson Cancer Center
First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	NCT01097746	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... FIGO Stage III ... FIGO Stage IIIA... FIGO Stage IIIA... FIGO Stage IIIA... FIGO Stage IIIA... FIGO Stage IIIA... FIGO Stage IIIB... FIGO Stage IIIC... FIGO Stage IVA ... FIGO Stage IVB ... Malignant Ovari... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Primary Periton...	Bevacizumab Carboplatin Paclitaxel	18 Years -	M.D. Anderson Cancer Center
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer	NCT02364713	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Platinum-Resist... Platinum-Resist... Platinum-Resist... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Bevacizumab Gemcitabine Hyd... Laboratory Biom... Oncolytic Measl... Paclitaxel Pegylated Lipos... Quality-of-Life... Topotecan Hydro...	18 Years -	Mayo Clinic
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion	NCT04919629	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Serous ... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Bevacizumab Biopsy Biospecimen Col... Pegcetacoplan Pembrolizumab Questionnaire A...	18 Years -	Roswell Park Cancer Institute
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	NCT00888615	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Brenner... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Elesclomol Sodi... Paclitaxel	18 Years -	GOG Foundation
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers	NCT02020707	Cervical Adenoc... Cervical Adenos... Cervical Adenos... Cervical Carcin... Cervical Squamo... Clinical Stage ... Endometrial Ade... Endometrial Cle... Endometrial End... Endometrial Mix... Endometrial Muc... Endometrial Ser... Endometrial Und... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Femal... Malignant Ovari... Malignant Ovari... Malignant Ovari... Malignant Ovari... Malignant Perit... Malignant Solid... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian High Gr... Ovarian Mucinou... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Platinum-Resist... Platinum-Resist... Platinum-Resist... Platinum-Sensit... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Unresectable Me... Uterine Corpus ...	Bevacizumab Laboratory Biom... Nab-paclitaxel Pharmacological...	18 Years -	Mayo Clinic

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: